Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris, and NASDAQ:
CYAD), a leader in the discovery and development of engineered cell therapies, with clinical
programs in cardiovascular disease and immuno-oncology, today announced that Steve
Buckanavage, Vice-President Global Marketing will be presenting for the company at the
Alliance for Regenerative Medicine’s 4th Annual Cell & Gene Therapy Investor Day in New
York City on Tuesday, March 22, 2016 at TIME EST.
Steve Buckanavage: “We are excited to participate in the conference and provide an
update on Celyad’s activities and key milestones in immune-oncology and cardiology for
- We believe our unique immuno-oncology approach in engineered T-Cells, with our
natural killer receptor program called NKR T-Cells, will generate interest on the part of peers
and investors.“
This event is organized by the Alliance for Regenerative Medicine (ARM) and co-hosted with
Piper Jaffray. A live-streaming webcast of all panels and company presentations will be
available at: http://www.arminvestorday.com/webcast and will be published on the event’s
website shortly after the conference.
